A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian Prediction
Kidney International · 2023-10 · 104 (4) · 840-850
DOI: 10.1016/j.kint.2023.06.021 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Kidney International, 2023-10. Verfasst von Nuria Lloberas und 15 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, Hospital Universitari de Bellvitge-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain. Electronic addr…. Hauptthemen laut MEDLINE: Kidney Transplantation, Tacrolimus. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
For three decades, tacrolimus (Tac) dose adjustment in clinical practice has been calculated empirically according to the manufacturer's labeling based on a patient's body weight. Here, we developed and validated a Population pharmacokinetic (PPK) model including pharmacogenetics (cluster CYP3A4/CYP3A5), age, and hematocrit. Our study aimed to assess the clinical applicability of this PPK model in the achievement of Tac Co (therapeutic trough Tac concentration) compared to the manufacturer's labelling dosage. A prospective two-arm, randomized, clinical trial was conducted to determine Tac starting and subsequent dose adjustments in 90 kidney transplant recipients. Patients were randomized to a control group with Tac adjustment according to the manufacturer's labeling or the PPK group adjusted to reach target Co (6-10 ng/ml) after the first steady state (primary endpoint) using a Bayesian prediction model (NONMEM). A significantly higher percentage of patients from the PPK group (54.8%) compared with the control group (20.8%) achieved the therapeutic target fulfilling 30% of the established superiority margin defined. Patients receiving PPK showed significantly less intra-patient variability compared to the control group, reached the Tac Co target sooner (5 days vs 10 days), and required significantly fewer Tac dose modifications compared to the control group within 90 days following kidney transplant. No statistically significant differences occurred in clinical outcomes. Thus, PPK-based Tac dosing offers significant superiority for starting Tac prescription over classical labeling-based dosing according to the body weight, which may optimize Tac-based therapy in the first days following transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nephrology Department, Hospital Universitari de Bellvitge-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain. Electronic address: nlloberas@ub.edu.
- Department of Clinical Sciences, Medicine Unit, University of Barcelona, Barcelona, Spain.
- Biopharmaceutics and Pharmacokinetics Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, School of Pharmacy, University of Barcelona, Barcelona, Spain. Electronic address: helena.colom@ub…
- Nephrology Department, Hospital Universitari de Bellvitge-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.
- Biochemistry Department, Hospital Universitari de Bellvitge-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.
Zitieren
APA
Lloberas, N., Grinyó, J. M., Colom, H., Vidal-Alabró, A., Fontova, P., Rigo-Bonnin, R., Padró, A., Bestard, O., Melilli, E., Montero, N., Coloma, A., Manonelles, A., Meneghini, M., Favà, A., Torras, J., & Cruzado, J. M. (2023). A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian Prediction. Kidney International, 104(4), 840-850. https://doi.org/10.1016/j.kint.2023.06.021
Vancouver
Lloberas N, Grinyó JM, Colom H, Vidal-Alabró A, Fontova P, Rigo-Bonnin R, et al. A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian Prediction. Kidney International. 2023;104(4):840-850. doi:10.1016/j.kint.2023.06.021
BibTeX
@article{Lloberas2023,
author = {Lloberas, Nuria and Grinyó, Josep M and Colom, Helena and Vidal-Alabró, Anna and Fontova, Pere and Rigo-Bonnin, Raul and Padró, Ariadna and Bestard, Oriol and Melilli, Edoardo and Montero, Nuria and Coloma, Ana and Manonelles, Anna and Meneghini, Maria and Favà, Alex and Torras, Joan and Cruzado, Josep M},
title = {A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian Prediction},
journal = {Kidney International},
year = {2023},
volume = {104},
number = {4},
pages = {840--850},
doi = {10.1016/j.kint.2023.06.021}
}
EUVIMED